Endo Axiom is an Australian biotechnology firm dedicated on preventing autoimmune illnesses and enhancing the quality of life for diabetics.
Endo Axiom has raised $698K in total funding. The most recent round was Grant. The last funding was announced in June 2025.
Endo Axiom's investors include MTPConnect.
Endo Axiom is headquartered in Haymarket, Australia.
Endo Axiom is an Australian biotechnology firm dedicated on preventing autoimmune illnesses and enhancing the quality of life for diabetics.
Endo Axiom is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endo Axiom — Funding & Investors." VCBacked, June 20, 2025, https://www.vcbacked.co/company/endo-axiom. Accessed August 14, 2026.
VCBacked. (2025). Endo Axiom — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/endo-axiom
{{cite web |title=Endo Axiom — Funding & Investors |url=https://www.vcbacked.co/company/endo-axiom |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated